Heidi Ko: Alarming Biomarker Testing Gaps in NSCLC

Heidi Ko, Medical Director, Medical Affairs, Labcorp Drug Development, posted the following on LinkedIn:

“These stats are alarming to me! Nearly 1 in 4 patients with nonsquamous, metastatic NSCLC fails to receive testing for even the most critical biomarkers for treatment determination: ALK, EGFR, and PD-L1. Interphysician and practice pattern variations among patient preference and goals of care are the most impactful factors contributing to the suboptimal ordering and guideline nonconformity.

We have to do better—time and time again, studies have shown that biomarkers testing correlates with improved survival.

I’ll be speaking at AMP2024 on current practice gaps and potential solutions to effectively implement precision oncology in the clinics, in collaboration with my wonderful colleagues from Illumina Marni Tierno, PhD, RN, Pratheesh Sathyan PhD, and Pierre del Moral, PhD MBA. Looking forward to a great interactive session on ways and interventions that we could do to better support testing practices!”

Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes

Authors: Jason M. Baron, Sarrah Widatalla, Matthew A. Gubens, and Farah Khalil

Source: Heidi Ko/LinkedIn